<DOC>
	<DOCNO>NCT01346540</DOCNO>
	<brief_summary>The LUME-Lung3 study 2 part : Run-in Phase I - Open label study identify Maximum Tolerated Dose BIBF 1120 add standard first-line treatment 3 weekly schedule gemcitabine cisplatin . Phase II - Placebo control efficacy study BIBF 1120 add standard 3 weekly cycle gemcitabine cisplatin therapy patient least Stable Disease 2 previous course chemotherapy</brief_summary>
	<brief_title>A Phase I/II Study Continuous Oral Treatment With BIBF 1120 Added Standard Gemcitabine/Cisplatin Therapy First Line NSCLC Patients With Squamous Cell Histology .</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Nintedanib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Inclusion criterion : Runin Phase I 1 . Histologically cytologically confirm diagnosis stage IIIB/IV recurrent Non Small Cell Lung Cancer ( NSCLC ) squamous cell histology . 2 . Measurable disease accord Response Evaluation Criteria Solid Tumours ( RECIST 1.1 ) . 3 . Patient Eastern Cooperative Oncology Group ( ECOG ) score 01 . 4 . Male female patient age = 18 year . 5 . Life expectancy least three ( 3 ) month . 6 . Written inform consent accordance International Conference Harmonisation Good Clinical Practice ( ICHGCP ) guideline . Phase II addition criterion : 7 . Radiologicallyconfirmed least stable disease 2 prior cycle cisplatin / gemcitabine chemotherapy . Exclusion criterion : 1 . Prior therapy advance metastatic recurrent Non Small Cell Lung Cancer ( NSCLC ) . One prior adjuvant , neoadjuvant adjuvant + neoadjuvant treatment allow least 12 month elapsed end treatment randomization 2 . Prior treatment Vascular Endothelial Growth Factor Receptor ( VEGFR ) inhibitor ( bevacizumab ) 3 . Any contraindication treatment gemcitabine and/or cisplatin . 4 . Use investigational drug within 4 week enter 1199.82 study . 5 . History major thrombotic clinically relevant bleed event past 6 month . 6 . Significant cardiovascular disease ( i.e . hypertension control medication . 7 . Surgery within 4 week ( except tumour biopsy ) prior randomisation incomplete wound heal . 8 . Active brain metastasis 9 . Radiotherapy ( except extremity ) within 3 month prior baseline image radiotherapy brain metastasis &lt; 4 week prior baseline image . 10 . Any current malignancy malignancy diagnose within past five ( 5 ) year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>